Strive, Inc. (ASST): Nasdaq/NYSE listing notice — Asset Entities Inc. receives Nasdaq minimum bid price deficiency notice; 180-day cure period until June 16, 2025

Strive, Inc.

Class B Common Stock (ASST) failed to maintain $1.00 minimum bid for 30 consecutive business days ended Dec 13, 2024.
Nasdaq notification received Dec 16, 2024; stock remains listed during cure period.
Company has until June 16, 2025 to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not cured, company may seek second 180-day period subject to meeting other listing standards.
Company intends to monitor bid price and may consider options including reverse stock split.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Strive, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 16, 2024, Asset Entities Inc., a Nevada corporation (the “Company”), received a written notification (the “Notification Letter”), from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market tier of Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides tha

View on SEC.gov

Browse all listing & compliance notices →

Strive, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-112672

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.